![]() | |
Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
UNII | |
Chemical and physical data | |
Formula | C25H29ClO6 |
Molar mass | 460.95 g·mol−1 |
3D model (JSmol) | |
| |
|
Janagliflozin is an SGLT2 inhibitor developed by Sihuan Pharmaceutical.[1][2][3][4][5][6] It is approved in China for the treatment of type 2 diabetes.[7]
| |
---|---|
SGLT1Tooltip Sodium-glucose transporter 1 |
|
SGLT2Tooltip Sodium-glucose transporter 2 |
|
SGLT1Tooltip Sodium-glucose transporter 1 & SGLT2Tooltip Sodium-glucose transporter 2 |
|
See also: Receptor/signaling modulators |